Alzheimer’s Drug Slows Disease Progression in Trial

their experimental Alzheimer’s disease drug

significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects for approval. The pharmaceutical companies said their drug lecanemab reduced cognitive and functional decline by 27%, compared with a placebo, over 18 months in a Phase 3 study of 1,800 patients with early-stage Alzheimer’s. The drug was also linked to higher rates of brain swelling and small bleeds, though the company said they were rarely symptomatic.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Newly Discovered Protein Connected to Significant Increase in Risk of Alzheimer’s DiseaseA mutation in the small protein SHMOOSE is linked with increased Alzheimer’s risk and highlights a possible target for treatment. A mutation in a newly discovered small protein is associated with a substantial increase in the risk for Alzheimer’s disease, according to a new University of Southe
Source: SciTechDaily1 - 🏆 84. / 68 Read more »

Fundraiser held to help 3-year-old Austin Rose with rare neurological diseaseA.J.'s family needs help to make his home accessible, to pay for nursing care and to travel to Ohio for clinical drug trials.
Source: cbschicago - 🏆 546. / 51 Read more »